Uterine Fibroid Treatment Drugs Market - By Drug Class (Progestin-releasing Intrauterine Device, Contraceptive, Gonadotropin-releasing Hormone Antagonist), Type (Submucosal, Intramural), Distribution Channel (Retail, Hospital), Global Forecast, 2023-2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUterine Fibroid Treatment Drugs Market Size
Uterine Fibroid Treatment Drugs Market size was valued to be USD 1.7 billion in 2022 and is projected to reach USD 4.5 billion by 2032 with a remarkable CAGR of 10%. The expansion can be credited to significant elements like the rising occurrence of uterine fibroids, the emergence of novel medications for individuals with uterine fibroids, and the heightened consciousness regarding uterine fibroids.
Uterine fibroids, also known as leiomyomas or myomas, refers to non-cancerous tumors or growth developed in the muscular wall of the uterus and are the most common type of benign tumors that affects the female reproductive system. Uterine fibroid treatment drugs are medications are provided to alleviate the symptoms of uterine fibroids or to prepare the patient for surgical interventions. These drugs facilitate in reducing the symptoms such as heavy menstrual bleeding, pain, and pressure by targeting the hormonal regulation of fibroid growth.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Uterine Fibroid Treatment Drugs Market Size in 2022 | USD 1.7 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 10% |
| 2032 Value Projection | USD 4.5 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 125 |
| Tables, Charts & Figures | 221 |
| Segments covered | Drug Class, Type, Distribution Channel, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
During the pandemic, numerous healthcare systems found themselves overwhelmed while dealing with COVID-19 patients. As a result, many non-urgent medical procedures, including interventions related to uterine fibroids, had to be postponed or even cancelled. This situation notably affected the usage of uterine fibroid drugs like GnRH agonists, commonly employed to shrink fibroids before surgical procedures. The manufacturing and distribution processes of several pharmaceutical companies were severely impacted due to lockdowns and travel restrictions.
Consequently, these challenges led to disruptions in the pharmaceutical supply chain, which encompassed products for uterine fibroid treatment as well. The availability of such drugs suffered, resulting in an adverse impact on the global market for uterine fibroid treatment drugs. Throughout the pandemic, the significance of telemedicine became evident as it allowed patients to receive a certain level of medical care remotely.
As the number of COVID-19 cases decreases, there has been a gradual return to normal operations in healthcare facilities and pharmaceutical manufacturing. This positive trend is contributing to the increased adoption and availability of women health devices and treatment, including those designed for uterine fibroid treatment.
Uterine Fibroid Treatment Drugs Market Driving Factors
The growth of the market is being propelled by several factors, including the increasing prevalence of uterine fibroids, the development of new drugs tailored for women with these fibroids, and the growing awareness surrounding this condition. According to an article titled "A Look at the Current State of Uterine Fibroid Care," published in Contemporary OB/GYN in 2022, it is estimated that by the age of 50, more than 70% of women will have experienced uterine fibroids.
Furthermore, data from the U.S. National Institutes of Health (NIH) indicates that uterine fibroids affect 20-25% of women of reproductive age. Notably, the impact is more pronounced in different racial groups, with up to 80% of black women and up to 70% of white women being affected by uterine fibroids by the age of 50. Although most commonly observed in women in their 40s and early 50s, uterine fibroids can also develop in younger women.
Given the rising incidence of uterine fibroids, there is an increasing demand for more effective and safer treatment drugs. This demand has spurred the development of innovative uterine fibroid treatment medications to meet the needs of the affected population.
Uterine Fibroid Treatment Drugs Market Analysis
Different types of medications are used to treat uterine fibroids. These medications can be grouped into different classes based on their mechanism of action. One class of medications includes progestin-releasing intrauterine devices (IUDs) and contraceptives, which are commonly used to manage uterine fibroids. In 2022, these medications accounted for about 65.7% of the market. They are expected to continue to grow in popularity, with an estimated growth rate of 9.9% over the next few years. Progestin-releasing IUDs and contraceptives have several advantages. They can help reduce heavy menstrual bleeding, relieve pain, shrink fibroids, and provide effective birth control. They are generally well-tolerated and have minimal side effects. Another class of medications includes gonadotropin-releasing hormone (GnRH) antagonists and agonists. These medications work by suppressing ovulation, which can help shrink fibroids and reduce symptoms. Non-hormonal medications and other drug classes are also available to treat uterine fibroids. The choice of medication for treating uterine fibroids depends on several factors, including the severity of symptoms, the patient's age and reproductive plans, and other medical conditions.
When it comes to treating uterine fibroids, there are different types of drugs used based on where the fibroids are located. These types includeSubmucosal fibroidsThese grow within the lining of the uterus and can cause heavy bleeding during periods. Progestins and GnRH agonists are common medications used to reduce bleeding and control fibroid growth. Intramural fibroids These are the most common type and grow within the muscular wall of the uterus. They can affect fertility and pregnancy, so treatment is important. Subserosal fibroidsThese grow on the outside of the uterus and may not cause symptoms. However, if they become large, they can put pressure on nearby organs. Pedunculated fibroids These are attached to the uterus by a stalk and can easily be removed surgically. In 2022, the market for submucosal fibroid treatment was valued at $608.8 million. It's expected to reach $1,589 million by 2032. Over the next decade, intramural fibroids are predicted to grow the fastest because they can cause serious issues with fertility and pregnancy.
When it comes to getting medicine for uterine fibroids, you have a few optionsretail pharmacies, hospital pharmacies, and other places. In 2022, most people (77.3%) bought these medicines from retail pharmacies. That's because they're easy to find over-the-counter (OTC). These include non-hormonal meds, birth control, painkillers, and other stuff. Plus, most people with uterine fibroids don't need surgery, so they can get their medicine at a regular pharmacy. Also, because people want to find safe and effective treatments, retail pharmacies are seeing more business.
In the next few years, the number of people getting treatment for uterine fibroids in North America is expected to shoot up by 9.4% each year. Why? Well, for starters, more and more women are being diagnosed with fibroids. And secondly, there's a growing demand for treatments that are non-invasive, easy on the body, and effective. Plus, more people have access to healthcare now. Also, big players in the industry, new drug approvals, and more awareness about fibroids are all giving the market a boost. But wait, there's more! In the Asia Pacific region, the market is expected to grow even faster – a whopping 10.9% each year, all because of the increasing number of women with fibroids in that area.
Uterine Fibroid Treatment Drugs Market Share
The key players in the uterine fibroid treatment drugs market are
- Pfizer Inc.
- Abbvie, Inc.
- AstraZeneca plc
- Bayer AG
- Myovant Sciences Gmbh
- Ferring B.V.
- Amring Pharmaceuticals Inc.
- Theramex and Watson Pharma, Inc.
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Uterine Fibroid Treatment Drugs Industry News
- In August 2022, MYFEMBREE, a product jointly developed by Pfizer, Inc. and Myovant Sciences, gained approval from the U.S. FDA for the management of moderate to severe pain associated with both menstrual and non-menstrual conditions. This regulatory endorsement facilitated their product's introduction to the market, thereby enriching their product portfolio.
- In June 2022, the European Commission approved the Yselty of Theramex, which is an oral GnRH antagonist. This strategy helped the company to strengthen its product portfolio and boosted their revenue.
The global uterine fibroid treatment drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
Market Size, By Drug Class
- Progestin-releasing intrauterine device (IUD)& contraceptives
- Gonadotropin-releasing hormone (GnRH) antagonists
- Gonadotropin-releasing hormone (GnRH) agonists
- Non-hormonal medications
- Other drug classes
Market Size, By Type
- Submucosal fibroids
- Intramural fibroids
- Subserosal fibroids
- Pedunculated fibroids
Market Size, By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Other distribution channels
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Switzerland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy